Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
October 03 2022 - 8:00AM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, today announced the
appointment of Rahul Singhvi, Sc.D., to its Board of Directors.
Dr. Singhvi is a biotechnology industry veteran
with more than three decades of research and development,
operations and commercialization expertise across his time with
Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc.
He currently serves as the Chief Executive Officer of National
Resilience, Inc. (Resilience), a technology-focused
biomanufacturing company, which he co-founded and built, with
end-to-end manufacturing and digital solutions across several
modalities including cell and gene therapies, nucleic acids,
vaccines and biologics.
“Rahul is a proven leader in the
biopharmaceutical industry, with a demonstrated track record of
enabling scale and accelerating the growth of innovative product
pipelines,” said Byron Dorgan, Chair of the Board of Codexis. “His
insights and guidance across drug development and driving adoption
of boundary-pushing technologies will prove invaluable throughout
Codexis’ evolution, and we are fortunate to welcome him to our
Board of Directors.”
“Codexis’ CodeEvolver® platform is a proven
engine to discover and develop novel, high performance enzymes and
biotherapeutics with unparalleled potential to drive real world
health benefits,” said Dr. Singhvi. “I am honored to join the
Company’s Board of Directors and look forward to partnering with
Codexis in support of its mission to apply the cutting-edge
advancements of enzyme engineering across a diverse range of
markets.”
Prior to Resilience, Dr. Singhvi was an
Operating Partner at Flagship Pioneering, a Boston-based life
sciences venture capital firm where he was responsible for founding
and operating companies launched from Flagship’s innovation
foundry, Flagship Labs. Before joining Flagship, Dr. Singhvi was
the Chief Operating Officer of Takeda’s Global Vaccine Business
Unit, where he oversaw the worldwide supply and expansion efforts
of all commercialized vaccines and development candidates within
the business unit. Previously, Dr. Singhvi was President and CEO of
Novavax (NASDAQ: NVAX) where he led the company’s transformation
from a specialty pharmaceutical business to a vaccine development
company. He has also previously served across a number of
biotherapeutics and healthcare companies as a board member, advisor
or executive team member, including Immunocellular Therapeutics,
Ltd. (OTC: IMUC), Univercells SA, and Valor Biotherapeutics LLC.
Dr. Singhvi began his professional career at Merck, where he held
roles across R&D and manufacturing. He has played a key
role in bringing bioengineering and microbiology innovations closer
to the clinic and is an author/co-author and listed inventor of
over ten peer-reviewed publications and three patents,
respectively. Dr. Singhvi holds M.S. and Sc.D. chemical engineering
degrees from MIT and a Bachelor of Technology degree from the
Indian Institute of Technology, Kanpur. He received an M.B.A. from
the Wharton School at the University of Pennsylvania.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver®C platform to discover and
develop novel, high performance enzymes and biotherapeutics.
Codexis enzymes have applications in the sustainable manufacturing
of pharmaceuticals, food, and industrial products; in the creation
of the next generation of life science tools; and as gene therapy
and oral enzyme therapies. The Company’s unique performance enzymes
drive improvements such as: reduced energy usage, waste generation
and capital requirements; higher yields; higher fidelity
diagnostics; and more efficacious therapeutics. Codexis enzymes
enable the promise of synthetic biology to improve the health of
people and the planet. For more information, visit
www.codexis.com.
Investor Relations Contact:
Argot PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024